Ranked #5,618 of 8,699 institutional investors
5AM Venture Management, LLC
San Francisco, CA
$241M
US stock portfolio at live prices · today −$1.1M (−0.45%)
Live prices, last trade 10:20 AM ET
- Value at quarter end (Q3 2026)
- $297M
- Change from Q2 2026
- +$9.1M (+3.17%)
- Positions
- 14 · 1 new, 1 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$25.1M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesLTGO 39.7%CAMP 8.66%TYRA 8.66%TRDA 7.09%TECX 5.32%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| LTGO Latigo Biotherapeutics, Inc. | 7,325,962 | $95.5M | 39.7% | New |
| CAMP Camp4 Therapeutics Corp | 5,277,216 | $20.8M | 8.66% | Reduced −10% |
| TYRA Tyra Biosciences, Inc. | 1,029,298 | $20.8M | 8.66% | Unchanged |
| TRDA Entrada Therapeutics, Inc. | 3,784,650 | $17.0M | 7.09% | Reduced −7% |
| TECX Tectonic Therapeutic, Inc. | 606,660 | $12.8M | 5.32% | Unchanged |
| CLDX Celldex Therapeutics, Inc. | 422,270 | $11.6M | 4.84% | Reduced −15% |
| SLN Silence Therapeutics plc | 476,200 | $9.4M | 3.92% | Unchanged |
| ARTV Artiva Biotherapeutics, Inc. | 2,353,304 | $9.2M | 3.81% | Unchanged |
| ZNTL Zentalis Pharmaceuticals, Inc. | 3,947,913 | $5.8M | 2.41% | Unchanged |
| MPLT MapLight Therapeutics, Inc. | 741,893 | $4.7M | 1.95% | Reduced −22% |
| ALXO ALX Oncology Holdings Inc. | 3,057,325 | $3.4M | 1.40% | Unchanged |
| TARA Protara Therapeutics, Inc. | 1,369,782 | $3.3M | 1.37% | Unchanged |
| SKYE Skye Bioscience, Inc. | 981,269 | $765K | 0.32% | Reduced −19% |
| EYPT EyePoint, Inc. | 1,050,000 | $272K | 0.11% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| SRZN Surrozen, Inc. | 271,250 | $8.1M |